Onconic Therapeutics (A476060) Stock Overview
Engages in the research and development of anti-cancer therapy in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A476060 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Onconic Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩15,710.00 |
| 52 Week High | ₩28,900.00 |
| 52 Week Low | ₩5,187.50 |
| Beta | 0 |
| 1 Month Change | -29.71% |
| 3 Month Change | -40.04% |
| 1 Year Change | 154.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 263.24% |
Recent News & Updates
Onconic Therapeutics' (KOSDAQ:476060) Shareholders Should Assess Earnings With Caution
Onconic Therapeutics Inc. ( KOSDAQ:476060 ) recently released a strong earnings report, and the market responded by...Onconic Therapeutics Inc. (KOSDAQ:476060) Stocks Shoot Up 36% But Its P/S Still Looks Reasonable
Onconic Therapeutics Inc. ( KOSDAQ:476060 ) shares have had a really impressive month, gaining 36% after a shaky period...Recent updates
Shareholder Returns
| A476060 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -3.3% | -5.6% | -9.9% |
| 1Y | 154.4% | 6.4% | 150.4% |
Return vs Industry: A476060 exceeded the KR Biotechs industry which returned 6.4% over the past year.
Return vs Market: A476060 exceeded the KR Market which returned 150.4% over the past year.
Price Volatility
| A476060 volatility | |
|---|---|
| A476060 Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A476060 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A476060's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 31 | John Kim | onconic.co.kr |
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer.
Onconic Therapeutics Inc. Fundamentals Summary
| A476060 fundamental statistics | |
|---|---|
| Market cap | ₩713.36b |
| Earnings (TTM) | ₩20.33b |
| Revenue (TTM) | ₩67.20b |
Is A476060 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A476060 income statement (TTM) | |
|---|---|
| Revenue | ₩67.20b |
| Cost of Revenue | ₩13.69m |
| Gross Profit | ₩67.19b |
| Other Expenses | ₩46.86b |
| Earnings | ₩20.33b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 447.67 |
| Gross Margin | 99.98% |
| Net Profit Margin | 30.25% |
| Debt/Equity Ratio | 0% |
How did A476060 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 17:33 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Onconic Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.